Header Logo

Connection

KAREN RABIN to Male

Back to Details
This is a "connection" page, showing publications KAREN RABIN has written about Male.
KAREN RABIN
Connection Strength
0.564
Male
  1. Interplay between Genetic Ancestry, Self-reported Race and Ethnicity, and Clinical Factors in Pediatric Acute Lymphoblastic Leukemia: A REDIAL Consortium Report. Cancer Epidemiol Biomarkers Prev. 2026 May 01; 35(5):710-717.
    View in: PubMed
    Score: 0.039
  2. An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance. Leukemia. 2021 06; 35(6):1777-1781.
    View in: PubMed
    Score: 0.027
  3. Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatr Blood Cancer. 2017 Sep; 64(9).
    View in: PubMed
    Score: 0.021
  4. First do no harm: infectious deaths in pediatric ALL. Blood. 2014 Aug 14; 124(7):987-9.
    View in: PubMed
    Score: 0.017
  5. Reply to "Peripheral blood lymphocyte recovery and overall survival in pediatric acute lymphoblastic leukemia". Pediatr Blood Cancer. 2014 Jan; 61(1):180.
    View in: PubMed
    Score: 0.016
  6. Attacking remaining challenges in childhood leukemia. N Engl J Med. 2012 Apr 12; 366(15):1445-6.
    View in: PubMed
    Score: 0.015
  7. Myelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Apr; 58(4):633-5.
    View in: PubMed
    Score: 0.014
  8. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Sep; 59(3):468-74.
    View in: PubMed
    Score: 0.014
  9. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009 Mar; 144(6):930-2.
    View in: PubMed
    Score: 0.012
  10. Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008 Aug; 51(2):171-7.
    View in: PubMed
    Score: 0.011
  11. Racial, Ethnic, and Neighborhood Disparities in Acute Kidney Injury in Pediatric Acute Leukemia. Cancer Med. 2026 May; 15(5):e71937.
    View in: PubMed
    Score: 0.010
  12. Lipidomic profiles associated with treatment related hepatotoxicity in children with acute lymphoblastic leukemia. Support Care Cancer. 2026 Feb 17; 34(3):209.
    View in: PubMed
    Score: 0.010
  13. Structural birth defects and leukemia risk in children with Down syndrome. Sci Rep. 2025 Dec 11; 16(1):1741.
    View in: PubMed
    Score: 0.010
  14. An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy. Blood Adv. 2025 Nov 25; 9(22):5802-5810.
    View in: PubMed
    Score: 0.010
  15. The impact of Indigenous American-like ancestry on the risk of acute lymphoblastic leukemia in Hispanic/Latino children. HGG Adv. 2026 Jan 15; 7(1):100534.
    View in: PubMed
    Score: 0.009
  16. Inferring chromosome segregation error stage and crossover in trisomic disorders with application to Down syndrome. Nat Commun. 2025 Jul 09; 16(1):6316.
    View in: PubMed
    Score: 0.009
  17. Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia. Oncologist. 2025 Jun 04; 30(6).
    View in: PubMed
    Score: 0.009
  18. Genome-Wide Association Studies of Down Syndrome Associated Congenital Heart Defects Suggests a Genetically Heterogeneous Risk for CHD in DS. Genet Epidemiol. 2025 Jun; 49(4):e70010.
    View in: PubMed
    Score: 0.009
  19. Ultra-low extracorporeal volume microfluidic leukapheresis is safe and effective in a rat model. Nat Commun. 2025 Feb 24; 16(1):1930.
    View in: PubMed
    Score: 0.009
  20. Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
    View in: PubMed
    Score: 0.009
  21. Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2025 Feb 27; 392(9):875-891.
    View in: PubMed
    Score: 0.009
  22. Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management. Pediatr Blood Cancer. 2025 Jan; 72(1):e31377.
    View in: PubMed
    Score: 0.009
  23. Cerebral Sinus Venous Thrombosis in Pediatric Acute Lymphoblastic Leukemia: Incidence, Clinical Characteristics, and Long-term Neurologic Outcomes. J Child Neurol. 2024 Nov; 39(13-14):494-499.
    View in: PubMed
    Score: 0.009
  24. Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3491-3503.
    View in: PubMed
    Score: 0.009
  25. Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatr Blood Cancer. 2024 Sep; 71(9):e31169.
    View in: PubMed
    Score: 0.009
  26. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. Lancet Haematol. 2023 Feb; 10(2):e129-e141.
    View in: PubMed
    Score: 0.008
  27. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. Lancet Haematol. 2022 Sep; 9(9):e678-e688.
    View in: PubMed
    Score: 0.008
  28. An updated assessment of 43,110 patients enrolled in the Childhood Cancer Research Network: A Children's Oncology Group report. Cancer. 2022 07 15; 128(14):2760-2767.
    View in: PubMed
    Score: 0.007
  29. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022 05 01; 128(9):1863-1870.
    View in: PubMed
    Score: 0.007
  30. Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. Leukemia. 2022 03; 36(3):648-655.
    View in: PubMed
    Score: 0.007
  31. Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia. Sci Rep. 2021 10 04; 11(1):19613.
    View in: PubMed
    Score: 0.007
  32. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol. 2021 Oct 01; 7(10):1521-1528.
    View in: PubMed
    Score: 0.007
  33. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 04; 68(4):e28929.
    View in: PubMed
    Score: 0.007
  34. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. J Clin Oncol. 2021 05 01; 39(13):1437-1447.
    View in: PubMed
    Score: 0.007
  35. The relationship between chronic health conditions and cognitive deficits in children, adolescents, and young adults with down syndrome: A systematic review. PLoS One. 2020; 15(9):e0239040.
    View in: PubMed
    Score: 0.007
  36. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 10 01; 38(28):3282-3293.
    View in: PubMed
    Score: 0.007
  37. Area deprivation is associated with poorer overall survival in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020 09; 67(9):e28525.
    View in: PubMed
    Score: 0.007
  38. Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. J Clin Oncol. 2020 08 10; 38(23):2628-2638.
    View in: PubMed
    Score: 0.007
  39. Six Candidate miRNAs Associated With Early Relapse in Pediatric B-Cell Acute Lymphoblastic Leukemia. Anticancer Res. 2020 Jun; 40(6):3147-3153.
    View in: PubMed
    Score: 0.007
  40. Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2020 06 08; 37(6):867-882.e12.
    View in: PubMed
    Score: 0.007
  41. Utilization of archived neonatal dried blood spots for genome-wide genotyping. PLoS One. 2020; 15(2):e0229352.
    View in: PubMed
    Score: 0.006
  42. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020 07; 34(7):1741-1750.
    View in: PubMed
    Score: 0.006
  43. Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer. 2020 02 01; 126(3):593-601.
    View in: PubMed
    Score: 0.006
  44. Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia. EBioMedicine. 2019 Oct; 48:49-57.
    View in: PubMed
    Score: 0.006
  45. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. Blood Adv. 2019 06 11; 3(11):1647-1656.
    View in: PubMed
    Score: 0.006
  46. Maternal Residential Proximity to Major Roadways and the Risk of Childhood Acute Leukemia: A Population-Based Case-Control Study in Texas, 1995-2011. Int J Environ Res Public Health. 2019 06 07; 16(11).
    View in: PubMed
    Score: 0.006
  47. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307.
    View in: PubMed
    Score: 0.006
  48. Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica. 2019 05; 104(5):986-992.
    View in: PubMed
    Score: 0.006
  49. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018 12 03; 215(12):3094-3114.
    View in: PubMed
    Score: 0.006
  50. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. 2018 10 10; 36(29):2926-2934.
    View in: PubMed
    Score: 0.006
  51. Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia. PLoS One. 2018; 13(5):e0197408.
    View in: PubMed
    Score: 0.006
  52. An overview of disparities in childhood cancer: Report on the Inaugural Symposium on Childhood Cancer Health Disparities, Houston, Texas, 2016. Pediatr Hematol Oncol. 2018 Mar; 35(2):95-110.
    View in: PubMed
    Score: 0.006
  53. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood. 2018 07 19; 132(3):264-276.
    View in: PubMed
    Score: 0.006
  54. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J Clin Oncol. 2018 05 01; 36(13):1330-1338.
    View in: PubMed
    Score: 0.006
  55. Family-based exome-wide association study of childhood acute lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility. PLoS One. 2017; 12(8):e0180488.
    View in: PubMed
    Score: 0.005
  56. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood. 2017 06 22; 129(25):3352-3361.
    View in: PubMed
    Score: 0.005
  57. Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. Leukemia. 2017 06; 31(6):1314-1324.
    View in: PubMed
    Score: 0.005
  58. Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics. Cancer. 2016 Dec 01; 122(23):3697-3704.
    View in: PubMed
    Score: 0.005
  59. The TGF-?/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016 Apr; 30(4):800-11.
    View in: PubMed
    Score: 0.005
  60. Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients. Am J Clin Pathol. 2015 Aug; 144(2):263-70.
    View in: PubMed
    Score: 0.005
  61. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 Oct; 62(10):1717-24.
    View in: PubMed
    Score: 0.005
  62. Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. Cancer Genet. 2015 Jan-Feb; 208(1-2):1-18.
    View in: PubMed
    Score: 0.004
  63. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014 Jan 02; 123(1):70-7.
    View in: PubMed
    Score: 0.004
  64. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
    View in: PubMed
    Score: 0.004
  65. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011 Aug; 25(8):1365-8.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.